New Data on RTH258 Show Promise New Data on RTH258 Show Promise

A recent phase 1/2 trial shows that RTH258 is a promising alternative to ranibizumab for the treatment of neovascular age-related macular degeneration.Medscape Ophthalmology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news